JP2013064024A5 - - Google Patents

Download PDF

Info

Publication number
JP2013064024A5
JP2013064024A5 JP2013006405A JP2013006405A JP2013064024A5 JP 2013064024 A5 JP2013064024 A5 JP 2013064024A5 JP 2013006405 A JP2013006405 A JP 2013006405A JP 2013006405 A JP2013006405 A JP 2013006405A JP 2013064024 A5 JP2013064024 A5 JP 2013064024A5
Authority
JP
Japan
Prior art keywords
carcinoma
mutation
patient
amino
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013006405A
Other languages
English (en)
Japanese (ja)
Other versions
JP5695680B2 (ja
JP2013064024A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013064024A publication Critical patent/JP2013064024A/ja
Publication of JP2013064024A5 publication Critical patent/JP2013064024A5/ja
Application granted granted Critical
Publication of JP5695680B2 publication Critical patent/JP5695680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013006405A 2005-11-11 2013-01-17 癌疾患の治療用キナゾリン誘導体 Active JP5695680B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05110656.5 2005-11-11
EP05110656 2005-11-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008539440A Division JP5688877B2 (ja) 2005-11-11 2006-11-09 癌疾患の治療用キナゾリン誘導体

Publications (3)

Publication Number Publication Date
JP2013064024A JP2013064024A (ja) 2013-04-11
JP2013064024A5 true JP2013064024A5 (enExample) 2013-10-03
JP5695680B2 JP5695680B2 (ja) 2015-04-08

Family

ID=37700909

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008539440A Active JP5688877B2 (ja) 2005-11-11 2006-11-09 癌疾患の治療用キナゾリン誘導体
JP2013006405A Active JP5695680B2 (ja) 2005-11-11 2013-01-17 癌疾患の治療用キナゾリン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008539440A Active JP5688877B2 (ja) 2005-11-11 2006-11-09 癌疾患の治療用キナゾリン誘導体

Country Status (5)

Country Link
US (5) US8404697B2 (enExample)
EP (2) EP1948179A1 (enExample)
JP (2) JP5688877B2 (enExample)
CA (3) CA2833706C (enExample)
WO (1) WO2007054550A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375259C (en) * 1999-06-21 2009-04-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
SI1948180T1 (sl) * 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
EP1981863B1 (en) * 2006-01-26 2012-10-10 Boehringer Ingelheim International GmbH Process for preparing aminocrotonylamino-substituted quinazoline derivatives
DK2068880T3 (da) * 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
UY31867A (es) * 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
EP2387401A1 (en) * 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
HUE044629T2 (hu) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
US20130012465A1 (en) * 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
PT2608792T (pt) * 2010-08-26 2018-01-15 Boehringer Ingelheim Int Métodos de administração de um inibidor de egfr
CN102382106A (zh) * 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
CN102382065B (zh) * 2010-08-30 2014-05-28 山东轩竹医药科技有限公司 苯胺取代的喹唑啉衍生物
CN102452989B (zh) * 2010-10-19 2014-10-22 山东轩竹医药科技有限公司 苯胺取代的喹唑啉衍生物
AU2012225693A1 (en) * 2011-03-04 2013-09-19 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CN102731485B (zh) * 2011-04-02 2016-06-15 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
WO2012155339A1 (zh) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
JP5859118B2 (ja) 2011-05-26 2016-02-10 山東軒竹医薬科技有限公司 チロシンキナーゼ阻害剤としてのキナゾリン誘導体、その調製方法及びその使用
WO2013135176A1 (zh) * 2012-03-16 2013-09-19 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
EP3473254B1 (en) * 2011-08-02 2024-01-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Phenothiazine derivatives for the treatment of autoimmune diseases
KR20160125527A (ko) 2012-04-17 2016-10-31 후지필름 가부시키가이샤 함질소 복소환 화합물 또는 그 염
US20150368230A1 (en) 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
WO2015007206A1 (zh) * 2013-07-16 2015-01-22 杭州普晒医药科技有限公司 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
CN105683167B (zh) 2013-10-16 2018-10-23 富士胶片株式会社 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CA2946538A1 (en) * 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP6257782B2 (ja) 2014-08-22 2018-01-10 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
CN105777656B (zh) * 2014-12-25 2018-02-02 深圳海王医药科技研究院有限公司 萘普替尼对甲苯磺酸盐的β晶型及制备方法和含有其的药物组合物
CN105777655B (zh) * 2014-12-25 2018-02-02 深圳海王医药科技研究院有限公司 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN107721987A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721985A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721986A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN109265449B (zh) * 2018-11-07 2021-11-23 沈阳工业大学 Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
WO2021209039A1 (zh) * 2020-04-17 2021-10-21 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
JPS6442472A (en) 1987-08-10 1989-02-14 Kanebo Ltd Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DK0707475T3 (da) 1993-06-14 1997-12-29 Janssen Pharmaceutica Nv Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
ATE212993T1 (de) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
IL120302A0 (en) 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DE19825591A1 (de) 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
BRPI9914164B8 (pt) 1998-09-29 2021-05-25 American Cyanamid Co compostos de 3-ciano quinolina
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1131304B1 (en) 1998-11-19 2002-12-04 Warner-Lambert Company N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
KR20020068261A (ko) 1999-02-27 2002-08-27 베링거 잉겔하임 파르마 카게 티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
DE19911366A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19908567A1 (de) 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2375259C (en) * 1999-06-21 2009-04-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
IL141235A (en) 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
NZ521117A (en) 2000-03-13 2005-02-25 Wyeth Corp Method of treating or inhibiting colonic polyps
US20060063752A1 (en) 2000-03-14 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
AU779695B2 (en) 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
WO2001077104A1 (de) 2000-04-08 2001-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10017539A1 (de) 2000-04-08 2001-10-11 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AT412213B (de) 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
WO2001094309A1 (en) 2000-06-02 2001-12-13 Shionogi & Co., Ltd. Drug composition antagonistic to both pgd2/txa2 receptors
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
DE10042064A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP1339458B1 (en) 2000-11-22 2007-08-15 Novartis AG Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
CN100448373C (zh) 2002-02-18 2009-01-07 味之素株式会社 保持了风味和香味的干粉及其制备方法
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
KR101064530B1 (ko) 2002-03-30 2011-09-14 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 티로신 키나아제 억제제로서의 4-(ｎ-페닐아미노)-퀴나졸린/퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10217689A1 (de) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20030225079A1 (en) * 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
US7223749B2 (en) * 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10326186A1 (de) 2003-06-06 2004-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU2004270016A1 (en) 2003-09-11 2005-03-17 Hadasit Medical Research Services And Development Ltd. Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy
ATE353888T1 (de) 2003-09-19 2007-03-15 Astrazeneca Ab Chinazolinderivate
JP2007507491A (ja) 2003-09-29 2007-03-29 シージェー コーポレーション 徐放性製剤
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10345875A1 (de) 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
PT1733056E (pt) * 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
WO2006017317A2 (en) 2004-07-12 2006-02-16 The General Hospital Corporation Method for the treatment of disease
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ZA200706804B (en) * 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
US20080145422A1 (en) 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
JP2008545688A (ja) 2005-05-25 2008-12-18 ワイス 置換３−シアノキノリン並びにその中間体を合成する方法
US20070009533A1 (en) 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
SI1948180T1 (sl) 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
JP5688877B2 (ja) * 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
EP1981863B1 (en) * 2006-01-26 2012-10-10 Boehringer Ingelheim International GmbH Process for preparing aminocrotonylamino-substituted quinazoline derivatives
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
CA2676244C (en) 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
EP2387401A1 (en) * 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
KR20120016053A (ko) 2009-05-14 2012-02-22 코오롱생명과학 주식회사 알킬아민 유도체의 제조방법
HUE044629T2 (hu) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
CN104736155B (zh) 2012-05-14 2018-01-02 杭州德润玉成生物科技有限公司 双环化合物作为激酶的抑制剂
CN103755688B (zh) 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 一种阿法替尼化合物的制备方法

Similar Documents

Publication Publication Date Title
JP2013064024A5 (enExample)
CN101678029B (zh) 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途
JPWO2020050890A5 (enExample)
JP2018109022A5 (enExample)
CY1124219T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τοπικο αναiσθητiκο οπως η βουπιβακαϊνη για τοπικη χορηγηση στο στομα ή τον φαρυγγα
JP2015508103A5 (enExample)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
RU2016122654A (ru) Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
JP2016535756A5 (enExample)
JP2014097929A5 (enExample)
PH12015501326A1 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
JP2016501221A5 (enExample)
JP2016528251A5 (enExample)
JP2015523397A5 (enExample)
JP2013523784A5 (enExample)
JPWO2021121367A5 (enExample)
JP2015536986A5 (enExample)
RU2014142057A (ru) Комплексная терапия
HRP20211652T1 (hr) Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze
JP2018502824A5 (enExample)
JP2019500380A5 (enExample)
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
RU2020108192A (ru) Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf
MX2023014589A (es) Compuestos anticancer.
Devaraja Current prospects of molecular therapeutics in head and neck squamous cell carcinoma